E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
acute exacerbation of chronic bronchitis |
|
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 9.1 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10000743 |
E.1.2 | Term | Acute exacerbation of chronic bronchitis |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
The primary objective is to compare the efficacy of moxifloxacin 400 mg PO OD for five days with the respective efficacy of amoxicillin clavulanic acid 875/125 mg PO BID for seven days in the treatment of subjects with AECB. The primary efficacy endpoint will be clinical failure rates at 8 weeks post-therapy visit in outpatients with AECB. Clinical failure is defined as the requirement for additional or alternate treatment (including increased dose or duration of treatment) for an exacerbation of respiratory symptoms, with systemic antibiotics and/or systemic corticosteroids and/or hospitalization with systemic antibiotic and/or systemic corticosteroid administration within 8 weeks post therapy. |
|
E.2.2 | Secondary objectives of the trial |
The secondary objectives will compare the following between the two treatment groups: •Clinical failure rates •Bacteriological eradication rates •Clinical failure rates (for subjects with positive sputum culture at enrollment; for each stratum) •Weekly mean symptom scores measured by the AECB-Symptom Scale (AECB-SS) •Rates and speed of symptom relief measured by the AECB-SS •Need for any change in dosage or additional respiratory medication such as bronchodilators and inhaled steroids, excluding short acting bronchodilators •Improvement in symptom burden measured by the AECB-SS •Improvement in health-related QoL measured by The St. George’s Hospital Respiratory Questionnaire (SGRQ) •Spirometry tests will be compared between treatment groups at each assessment visit •Healthcare resource utilization/consumption related to chronic bronchitis management •Safety and tolerability of moxifloxacin versus amoxicillin clavulanic acid, with particular attention to rates of diarrhea |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
1.Outpatients with chronic bronchitis 2.Male or female subjects, greater than or equal to 60 years old 3.Subject who can be managed with oral antimicrobials 4.Post bronchodilatory FEV1 less than or equal to 60% predicted and FEV1/FVC less than 70% at enrollment. 5.Documented history of 2 or more AECB episodes, within 12 months of study enrollment, requiring a course of systemic antibiotics and/or systemic corticosteroids 6.All symptoms/signs must be present and confirmed by the Investigator: •Increase in dyspnea •Purulent sputum •Increase in sputum volume 7.Subject must provide a sputum sample. The sputum will be assessed macroscopically by the investigator and should be graded as either yellow, green or rust (according to the provided color chart). 8.Current or past cigarette smoker with great than or equal to 20 pack year smoking history 9.Subjects must be exacerbation-free for at least 30 days prior to enrollment 10.Subjects must be willing and able to complete the questionnaires and subject booklet without assistance 11.Subjects with medical conditions and social status at the time of enrollment compatible with study protocol procedures 12.Willing and able to provide written informed consent |
|
E.4 | Principal exclusion criteria |
1.Known hypersensitivity to quinolones, ß-lactams, or to any of the excipients of the study drugs 2.Pregnant or breast feeding women (women of childbearing potential, based on investigator assessment must have negative urinary pregnancy test) 3.Known to have congenital or acquired QT prolongation 4.Known to have clinically relevant bradycardia 5.Known to have clinically relevant heart failure with reduced left ventricular ejection fraction 6.Known to have previous history of symptomatic arrhythmias 7.Taking QT prolonging drugs, for example class IA or III antiarrhythmic agents (e.g., quinidine, procainamide, amiodarone, sotalol), neuroleptics (e.g., phenothiazines, pimozide, sertindole, haloperidol, sultopride), tricyclic antidepressants, certain antihistaminics (e.g., terfenadine, astemizole, mizolastine), certain antimicrobials (sparfloxacin, erythromycin IV, pentamidine, antimalarials particularly halofantrine) or other QT prolonging drugs (e.g., cisapride, vincamine iv, bepridil, and diphemanil) 8.Known electrolyte disturbances that are not controlled, particularly uncorrected hypokalemia 9.Known history of hereditary problems of galactose intolerance, the Lapp lactase deficiency, or glucose-galactose malabsorption 10.History of a tendon disease/disorder 11.Known history of liver dysfunction (Child-Pugh C), including known elevated transaminases (ALT and/or AST greater than 5 times the upper limit of normal) 12.Known severe renal impairment with glomerular filtration rate of <30mL/min 13.Known neutropenia (neutrophil count <1000/mm3) caused by immunosuppressive therapy or malignancy 14.Known to have AIDS (CD4 count of <200/mm3), or be HIV positive and receiving Highly Active Anti-Retroviral Therapy (HAART) (HIV testing is not mandatory) 15.Known chronic asthma (>15% reversibility or at least 200 mL), bronchial carcinoma, active pulmonary tuberculosis, known diffuse bronchiectasis, cystic fibrosis, or pneumonia (a chest X-ray is not mandatory) 16.Known history of chronic colonization of pathogenic organisms resistant to moxifloxacin and/or amoxicillin clavulanic acid (e.g., Pseudomonas aeruginosa, MRSA) 17.Receiving long term (>4 consecutive weeks) systemic corticosteroid treatment (>10 mg/day of prednisolone or equivalent) 18.Received short course of systemic corticosteroid treatment within 30 days prior to enrollment 19.Unable to take oral medication 20.Life expectancy of less than 6 months 21.Receiving systemic antibacterial therapy within 30 days prior to study enrollment 22.Requiring concomitant systemic antibacterial agents 23.Use of any investigational drug or device within 30 days of screening, or previously enrolled in this study 24.Requiring home ventilatory support (subjects requiring home/portable oxygen therapy or CPAP for sleep apnea are not excluded) and/or those who have a tracheotomy in situ 25.History of liver function disorders following previous treatment with amoxicillin-clavulanic acid 26. Receiving disulfiram therapy
|
|
E.5 End points |
E.5.1 | Primary end point(s) |
The primary efficacy criterion are clinical failure rates at the follow-up visit 8 weeks after end of treatment. Clinical failure is defined as the requirement for additional or alternate treatment (including increased dose or duration of treatment) for an exacerbation of respiratory symptoms, with systemic antibiotics, and/or systemic corticosteroids, and/or hospitalization with systemic antibiotic and/or systemic corticosteroid administration within 8 weeks post therapy. |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | Yes |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | Yes |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | Yes |
E.8.1.5 | Parallel group | Yes |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | Yes |
E.8.1.7.1 | Other trial design description |
|
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | Yes |
E.8.2.2 | Placebo | Yes |
E.8.2.3 | Other | No |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.5 | The trial involves multiple Member States | Yes |
E.8.5.1 | Number of sites anticipated in the EEA | 109 |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | Yes |
E.8.6.2 | Trial being conducted completely outside of the EEA | Information not present in EudraCT |
E.8.6.3 | If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned |
|
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
The end of study is defined as clean database. |
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 2 |
E.8.9.1 | In the Member State concerned months | 2 |
E.8.9.1 | In the Member State concerned days | |
E.8.9.2 | In all countries concerned by the trial years | 2 |
E.8.9.2 | In all countries concerned by the trial months | 2 |